General Information of Drug (ID: DMA2B5Y)

Drug Name
DS-3032 Drug Info
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
73297272
TTD Drug ID
DMA2B5Y

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7388 DMF5GZI Acute myeloid leukaemia 2A60 Phase 3 [4]
APG-115 DMIFA0L Prolymphocytic leukaemia 2A82.1 Phase 2 [1]
ALRN-6924 DMLBWT1 Haematological malignancy 2B33.Y Phase 2 [1]
AMG 232 DM65PTO Merkel cell carcinoma 2C34 Phase 2 [5]
ASTX295 DM9EM5G Solid tumour/cancer 2A00-2F9Z Phase 1/2 [6]
HDM201 DMVRTCW Haematological malignancy 2B33.Y Phase 1 [1]
RG7775 DMXBS6U Acute myeloid leukaemia 2A60 Phase 1 [7]
JNJ-26854165 DMNSJ3C Non-small-cell lung cancer 2C25.Y Phase 1 [8]
BI 907828 DM2Z4YQ Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
MI-219 DM196LK Triple negative breast cancer 2C60-2C65 Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ubiquitin-protein ligase E3 Mdm2 (MDM2) TT08GJW MDM2_HUMAN Inhibitor [3]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01877382) A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
3 Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36.
4 Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
5 Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.
6 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
7 Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche.
8 Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741.
9 MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874.
10 MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26.